(Bloomberg) -- CVC Capital Partners is considering a sale of Theramex in a deal that could value the women’s health business at more than $1 billion, according to people familiar with the matter. 

The private equity firm is working with Rothschild & Co. as it explores a possible sale of the asset, the people said, asking not to be identified discussing confidential information. Theramex could appeal to other buyout groups seeking to bolster their health-care portfolios, the people said. 

Deliberations are ongoing and there’s no certainty they’ll result in a sale, according to the people. Representatives for CVC, Rothschild and Theramex declined to comment. 

CVC agreed to buy Teva Pharmaceutical Industries Ltd.’s women’s health assets in 2017 and created a new company called Theramex, which today employs more than 400 people in over 80 countries. Theramex provides fertility treatments and contraceptives, among other products, according to its website. 

A possible sale of the business comes at a time of heightened deal activity in the health-care industry, fueled by the Covid-19 pandemic. Advent International and KKR & Co. are among the buyout firms studying potential bids for the international drugstore business being sold by Walgreens Boots Alliance Inc., Bloomberg News reported last week.

©2022 Bloomberg L.P.